Drugs / HL-400
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT06997484 Comparator | Apr 2025 → Jun 2026 overdue | Parkinson disease | Highlightll Pharmaceutical (USA) LLC | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HL-400 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06997484 ↗ |
| Action | Inhibit | “HL-400 (a NLRP3 inhibitor)” NCT06997484 ↗ |
| Route | Oral | “following oral single and multiple ascending dose administration” NCT06997484 ↗ |
| Target | NLRP3 | “HL-400 (a NLRP3 inhibitor)” NCT06997484 ↗ |